Skip to main navigation Skip to search Skip to main content

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

  • Fredrik H. Schjesvold*
  • , Nicolaas A. Bakker
  • , Pieter Sonneveld
  • *Corresponding author for this work
  • University of Oslo
  • Oncopeptides AB

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

3 Citations (Scopus)
100 Downloads (Pure)
Original languageEnglish
Article number101528
JournalTranslational Oncology
Volume25
DOIs
Publication statusPublished - Nov 2022

Bibliographical note

2022 The Authors. Published by Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this